NRIX Company Profile and Key Details

Q: Who are the executives of NRIX?

Mr. Howard A. Simon J.D., Esq., SPHRVice President of Operations & Corporation CounselDr. Christine RingGen. Counsel & Sec.Rita KwongSenior Accounting Mang.Mr. Howard A. Simon Esq., J.D., SPHRVice President of Operations & Corporation CounselMs. Stefani A. WolffChief Operating Officer & Executive Vice President of Product Devel.Dr. Gwenn M. Hansen Ph.D.Chief Scientific OfficerDr. Arthur T. Sands M.D., Ph.D.Chief Executive Officer, Pres & DirectorMr. Johannes Van HouteChief Financial OfficerDr. John Kuriyan Ph.D.Founder & Member of Scientific Advisory BoardDr. Michael Rapé Ph.D.Founder & Member of Scientific Advisory BoardProf. Arthur Weiss M.D., Ph.D.Founder & Member of Scientific Advisory BoardMr. Eric C. Schlezinger J.D.Chief People OfficerDr. Arthur Weiss M.D., Ph.D.Founder & Member of Scientific Advisory BoardDr. Michael T. Lotze F.A.C.S., M.D.Chief Cellular Therapy OfficerDr. Christine Ring J.D., Ph.D.Gen. Counsel & Sec.Dr. Jason Kantor Ph.D.Executive Vice President of Fin. & Bus. Strategy

NASDAQ : NRIX

Nurix Therapeutics

$25.10

-0.71-2.75%

Open: 4:00 PM

59.19

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Price Chart

Stock Price Today

Nurix Therapeutics, Inc. (NRIX) stock declined over -2.75%, trading at $25.10 on NASDAQ, down from the previous close of $25.81. The stock opened at $26.31, fluctuating between $25.02 and $26.65 in the recent session.

Stock Snapshot

25.81

Prev. Close

2.6B

Market Cap

25.015

Day Low

-7.28

P/E Ratio

-3.45

EPS (TTM)

-1.62

Cash Flow per Share

26.31

Open

103.78M

Number of Shares

26.65

Day High

98.01%

Free Float in %

3.07

Book Value

1.32M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Sep 11, 2026	26.31	26.65	25.00	25.10	1.32M
Sep 10, 2026	25.89	25.99	25.50	25.81	1.03M
Sep 09, 2026	26.46	26.70	25.91	26.26	1.01M
Sep 08, 2026	25.42	26.42	25.36	26.13	1.29M
Sep 04, 2026	25.19	26.22	24.97	26.14	1.23M
Sep 03, 2026	25.82	26.16	24.95	25.32	1.15M
Sep 02, 2026	26.35	26.92	25.39	25.82	1.55M
Sep 01, 2026	25.47	26.11	25.47	26.04	1.32M
Aug 31, 2026	26.00	26.23	25.17	25.78	1.22M
Aug 28, 2026	26.52	26.87	26.13	26.21	908.26K
Aug 27, 2026	26.80	27.50	26.24	26.88	1.26M
Aug 26, 2026	26.77	27.23	26.44	26.71	551.87K
Aug 25, 2026	26.72	27.38	26.38	26.95	1.02M
Aug 24, 2026	26.37	26.69	25.86	26.27	874.2K
Aug 21, 2026	27.41	27.50	26.70	26.72	1.49M
Aug 20, 2026	27.33	27.57	26.68	27.05	1.05M
Aug 19, 2026	27.50	28.23	27.02	27.79	2.1M
Aug 18, 2026	26.51	27.04	26.51	26.93	815.3K
Aug 17, 2026	26.62	27.22	26.50	27.17	1.15M
Aug 14, 2026	27.01	27.25	26.19	27.05	738.22K

Contact Details

Brisbane, CA 94005

United States

https://www.nurixtx.com 415 660 5320

About Company

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton’s tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in Brisbane, California.

Stock Peers

ARGX

0.35+0.04%

argenx SE$984.39 REGN

-11.77-1.48%

Regeneron Pharmaceuticals, Inc.$781.49 MDGL

1.37+0.26%

Madrigal Pharmaceuticals, Inc.$534.49 VRTX

0.88+0.17%

Vertex Pharmaceuticals Incorporated$515.44 UTHR

-6.75-1.34%

United Therapeutics Corporation$497.11 KRYS

1.45+0.42%

Krystal Biotech, Inc.$347.00 ONC

4.71+1.38%

BeOne Medicines AG$346.51 PRAX

-3.99-1.18%

Praxis Precision Medicines, Inc.$334.58 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 LGND

-4.78-1.65%

Ligand Pharmaceuticals Incorporated$284.47

Company Overview

Nurix Therapeutics, Inc. (NASDAQ:NRIX) closed at $25.10 USD, losing -$0.71 (-2.75%) from the previous close of $25.81. The stock is currently mid-range between its 52-week high and low $8.20 and $28.23. With a market capitalization of about $2.60 billion, Nurix Therapeutics, Inc. is classified as a mid-cap and shows higher-than-market volatility (beta ~1.80). Key stats such as the average daily volume over the past year has been around 1.53 million shares, in line with its 52-week average. Headquartered in Brisbane, CA, Nurix Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Arthur T. Sands, the company employs approximately 317 people and listed since July 24, 2020. Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases.

Technical Performance

Short-term trend indicators are mixed aligned (SMA20 -0.53%, SMA50 -9.11%, SMA200 22.88%). The stock’s 14-day RSI is 45.28 (neutral), while the ATR of 0.9 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -28.4% below its high and over 96.94% above its low. Average 10-day trading volume of 1.23 million shares is below the 3-month average of 1.48 million, indicating normal recent market interest.

Valuation Metrics

Nurix Therapeutics, Inc. trades at a P/E ratio of -7.32, slightly below the S&P 500 average, with a price-to-sales ratio of 71.32 and a price-to-book ratio of 6.97 trading at moderately above to book value. The P/FCF stands at -8.61, also below market averages.

Dividend & Fair Value

Nurix Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$6.28. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Nurix Therapeutics, Inc. generated EPS of -$3.04 over the past year. Five-year average earnings growth is -2.04%. Wall Street analysts project EPS growth of 6.26% annually over the next five years. The latest quarter delivered EPS of -$0.81. The next quarter is forecast at -$0.76. Next year's EPS is expected at -$28.83. Analyst sentiment is bullish. Analyst rating data shows there are 16 Strong Buy ratings, 35 Buy ratings, 1 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $45.00 to $15.00. The high target offers 79.28% upside. The low target suggests -40.24% downside. The mean target is $30.65. This offers 22.11% upside. Nurix Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended July 09, 2026, missed forecasts by 12.5%. The prior quarter beat by 3.95%. Over the last six quarters, Apple has recorded several small beats. These include -6.94% in April 08, 2025.

Shareholding & Insider Activity

Nurix Therapeutics, Inc. has 103.78 million shares outstanding. The public float is 79.65 million shares, elevated short interest at 17.88% of float. This equals 18.35 million shares. The short ratio is 15.24 days. Institutional investors hold 116.41% of the float. Insiders own 1.08%. Hansen Gwenn holds 117.23 thousand shares, van Houte Hans has 40.17 thousand shares and Ring Christine has 9.11 thousand shares. Over the past six months, insider transactions show net selling. They sold 123.49 thousand shares across 20 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Nurix Therapeutics generated $54.55M in revenue, or $0.81 per share. Gross margin was 100.00%, operating margin -390.52%, and net profit margin -354.85%. Returns are negative, with ROA at -53.10% and ROE at -96.55%.
On valuation metrics, Nurix Therapeutics trades at a P/E of -7.32, P/S of 71.32 and P/B of 6.97. The current ratio is 6.34 and quick ratio is 6.34. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is -45.65 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 0.14, supported by a cash flow-to-debt ratio of -5.05.

Quarterly Financial Highlights

For the quarter ended Nov 30, 2024, Nurix Therapeutics posted revenue of $54.55M, down slightly from $76.99M in the prior quarter. Gross profit was $54.55M (margin 100.00%). Operating income was - $213.03M (margin -390.5%). Net income was- $193.57M (EPS - $2.88).
The company ended the quarter with $287.91M in cash and short-term investments, a total debt of $30.61M, and net debt of - $24.01M. Total assets were $364.54M, with equity of $200.49M. Financials further reflected weakness, with operating cash flow of - $81.37M, free cash flow of - $89.77M, and capital expenditures of - $8.40M.

Price Forecast & Outlook

Our AI price prediction model suggests that Nurix Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -2.67%, with price expected at $24.43 by September 25, 2026, within a range of $23.79 to $25.04 3-Month Outlook: Projected rise of 242.99%, reaching $86.09 by December 10, 2026, with a range of $85.60 to $86.84. 1-Year Outlook: Projected gain of 15.82%, with price at $29.07 by September 10, 2027, within a range of $27.08 to $31.04.

Key Takeaways

Nurix Therapeutics, Inc. (NASDAQ:NRIX) shares are flat -3.85% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Nurix Therapeutics, Inc. trading at a premium to the broader market with a P/E of -7.32. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $31.21, suggesting 24.34% upside. Our AI forecast model points to short-term weakness (-2.67% over two weeks), a medium-term rise (242.99% over three months), and a longer-term gain (15.82% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Nurix Therapeutics, Inc. (NRIX) stock price?

Nurix Therapeutics, Inc. (NASDAQ: NRIX) stock price is $25.10 in the last trading session. During the trading session, NRIX stock reached the peak price of $26.65 while $25.02 was the lowest point it dropped to. The percentage change in NRIX stock occurred in the recent session was -2.75% while the dollar amount for the price change in NRIX stock was - $0.71.

NRIX's industry and sector of operation?

The NASDAQ listed NRIX is part of Biotechnology industry that operates in the broader Healthcare sector. Nurix Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of NRIX?

Mr. Howard A. Simon J.D., Esq., SPHR
Vice President of Operations & Corporation Counsel
Dr. Christine Ring
Gen. Counsel & Sec.
Rita Kwong
Senior Accounting Mang.
Mr. Howard A. Simon Esq., J.D., SPHR
Vice President of Operations & Corporation Counsel
Ms. Stefani A. Wolff
Chief Operating Officer & Executive Vice President of Product Devel.
Dr. Gwenn M. Hansen Ph.D.
Chief Scientific Officer
Dr. Arthur T. Sands M.D., Ph.D.
Chief Executive Officer, Pres & Director
Mr. Johannes Van Houte
Chief Financial Officer
Dr. John Kuriyan Ph.D.
Founder & Member of Scientific Advisory Board
Dr. Michael Rapé Ph.D.
Founder & Member of Scientific Advisory Board
Prof. Arthur Weiss M.D., Ph.D.
Founder & Member of Scientific Advisory Board
Mr. Eric C. Schlezinger J.D.
Chief People Officer
Dr. Arthur Weiss M.D., Ph.D.
Founder & Member of Scientific Advisory Board
Dr. Michael T. Lotze F.A.C.S., M.D.
Chief Cellular Therapy Officer
Dr. Christine Ring J.D., Ph.D.
Gen. Counsel & Sec.
Dr. Jason Kantor Ph.D.
Executive Vice President of Fin. & Bus. Strategy

How NRIX did perform over past 52-week?

NRIX's closing price is 206.28% higher than its 52-week low of $8.20 where as its distance from 52-week high of $28.23 is -11.09%.

How many employees does NRIX have?

Number of NRIX employees currently stands at 317.

Link for NRIX official website?

Official Website of NRIX is: https://www.nurixtx.com

How do I contact NRIX?

NRIX could be contacted at phone 415 660 5320 and can also be accessed through its website. NRIX operates from 1600 Sierra Point Parkway, Brisbane, CA 94005, United States.

How many shares of NRIX are traded daily?

NRIX stock volume for the day was 1.32M shares. The average number of NRIX shares traded daily for last 3 months was 1.53M.

What is the market cap of NRIX currently?

The market value of NRIX currently stands at $2.60B with its latest stock price at $25.10 and 103.78M of its shares outstanding.

Employees	317
Beta	1.8
Sales or Revenue	$54.55M
5Y Sales Change%	-0.391%
Fiscal Year Ends	November
Sector	Healthcare
Industry	Biotechnology

NRIX Company Profile and Key Details

Nurix Therapeutics

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Dividend & Fair Value

Earnings & Analyst Outlook

Company Overview

Technical Performance

Financial & Profitability Overview

Quarterly Financial Highlights

Shareholding & Insider Activity

Key Takeaways

Price Forecast & Outlook

Valuation Metrics